Cercar
01/09/2023
Update of the recommendations on the management of the SARS-CoV-2 coronavirus pandemic (COVID-19) in kidney transplant patients
Mazuecos, A, Villanego, F, Alonso, A, Beneyto, I, Crespo, M, Diaz-Corte, C, Franco, A, Gonzalez-Roncero, F, Guirado, L, Jimenez, C, Juega, J, Llorente, S, Paul, J, Rodriguez-Benot, A, Ruiz, JC, Sanchez-Fructuoso, A, Torregrosa, V, Rodrigo, E, Hernandez, D, Lopez, V, Lopez-Oliva, M, Zarraga, S. Update of the recommendations on the management of the SARS-CoV-2 coronavirus pandemic (COVID-19) in kidney transplant patients. NEFROLOGIA. 2023; 43(5)DOI:10.1016/j.nefro.2022.11.001. PMID:37957107. IF:2.000(Q2/5D).
01/08/2023
Effect of Immunosuppressive Treatments on Kidney Outcomes After Gross Hematuria-Related Acute Kidney Injury in Older Patients With IgA Nephropathy
Sevillano, AM, Caravaca-Fontan, F, Garcia-Galan, LC, Fernandez-Juarez, G, Lopez-Revuelta, K, Guzman, DA, Martin-Reyes, G, Quintana, LF, Rodas, LM, de la Nieta, MDS, Rabasco, C, Espinosa, M, Diaz-Encarnacion, M, San Miguel, L, Barrios, C, Rodriguez, E, Garcia, P, Valera, A, Pena, JK, Shabaka, A, Velo, M, Sierra, M, Gonzalez, F, Fernandez-Reyes, MJ, Heras, M, Delgado, P, Gutierrez, E, Moreno, JA, Praga, M. Effect of Immunosuppressive Treatments on Kidney Outcomes After Gross Hematuria-Related Acute Kidney Injury in Older Patients With IgA Nephropathy. Kidney International Reports. 2023; 8(8)DOI:10.1016/j.ekir.2023.05.027. PMID:37547537. IF:5.700(Q1/1D).
19/06/2023
Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy
Kiryluk, K, Sanchez-Rodriguez, E, Zhou, XJ, Zanoni, F, Liu, LL, Mladkova, N, Khan, A, Marasa, M, Zhang, JY, Balderes, O, Sanna-Cherchi, S, Bomback, AS, Canetta, PA, Appel, GB, Radhakrishnan, J, Trimarchi, H, Sprangers, B, Cattran, DC, Reich, H, Pei, YR, Ravani, P, Galesic, K, Maixnerova, D, Tesar, V, Stengel, B, Metzger, M, Canaud, G, Maillard, N, Berthoux, F, Berthelot, L, Pillebout, E, Monteiro, R, Nelson, R, Wyatt, RJ, Smoyer, W, Mahan, J, Samhar, A, Hidalgo, G, Quiroga, A, Weng, PTC, Sreedharan, R, Selewski, D, Davis, K, Kallash, M, Vasylyeva, TL, Rheault, M, Chishti, A, Ranch, D, Wenderfer, SE, Samsonov, D, Claes, DJ, Akchurin, O, Goumenos, D, Stangou, M, Nagy, J, Kovacs, T, Fiaccadori, E, Amoroso, A, Barlassina, C, Cusi, D, Del Vecchio, L, Battaglia, GG, Bodria, M, Boer, E, Bono, L, Boscutti, G, Caridi, G, Lugani, F, Ghiggeri, G, Coppo, R, Peruzzi, L, Esposito, V, Esposito, C, Feriozzi, S, Polci, R, Frasca, G, Galliani, M, Garozzo, M, Mitrotti, A, Gesualdo, L, Granata, S, Zaza, G, Londrino, F, Magistroni, R, Pisani, I, Magnano, A, Marcantoni, C, Messa, P, Mignani, R, Pani, A, Ponticelli, C, Roccatello, D, Salvadori, M, Salvi, E, Santoro, D, Gembillo, G, Savoldi, S, Spotti, D, Zamboli, P, Izzi, C, Alberici, F, Delbarba, E, Florczak, M, Krata, N, Mucha, K, Paczek, L, Niemczyk, S, Moszczuk, B, Panczyk-Tomaszewska, M, Mizerska-Wasiak, M, Perkowska-Ptasinska, A, Baczkowska, T, Durlik, M, Pawlaczyk, K, Sikora, P, Zaniew, M, Kaminska, D, Krajewska, M, Kuzmiuk-Glembin, I, Heleniak, Z, Bullo-Piontecka, B, Liberek, T, Debska-Slizien, A, Hryszko, T, Materna-Kiryluk, A, Miklaszewska, M, Szczepanska, M, Dyga, K, Machura, E, Siniewicz-Luzenczyk, K, Pawlak-Bratkowska, M, Tkaczyk, M, Runowski, D, Kwella, N, Drozdz, D, Habura, I, Kronenberg, F, Prikhodina, L, van Heel, D, Fontaine, B, Cotsapas, C, Wijmenga, C, Franke, A, Annese, V, Gregersen, PK, Parameswaran, S, Weirauch, M, Kottyan, L, Harley, JB, Suzuki, H, Narita, I, Goto, S, Lee, HJ, Kim, DK, Kim, YS, Park, JH, Cho, BL, Choi, M, Van Wijk, A, Huerta, A, Ars, E, Ballarin, J, Lundberg, S, Vogt, B, Mani, LY, Caliskan, Y, Barratt, J, Abeygunaratne, T, Kalra, PA, Gale, DP, Panzer, U, Rauen, T, Floege, J, Schlosser, P, Ekici, AB, Eckardt, KU, Chen, N, Xie, JY, Lifton, RP, Loos, RJF, Kenny, EE, Ionita-Laza, I, Kottgen, A, Julian, BA, Novak, J, Scolari, F, Zhang, H, Gharavi, AG. Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy. NATURE GENETICS. 2023; 55(7)DOI:10.1038/s41588-023-01422-x. PMID:37337107. IF:31.800(Q1/1D).
27/05/2023
Trial design of the MOTheR HDx study: a multicenter, open-label, prospective, randomized study to explore the morbidity and mortality in patients dialyzed with the Theranova HDx in comparison with online hemodiafiltration
de Sequera, P, Perez-Garcia, R, Vega, A, Martinez-Vaquera, S, Acosta, JG, Del Valle, KP, Fernandez-Lucas, M, Garcia-Rubiales, MA, Garcia-Herrera, AL, Coll, E, Merida, E, Martinez-Miguel, P, Castano, I, Gil-Casares, B, Garro, J, Maduel, F. Trial design of the MOTheR HDx study: a multicenter, open-label, prospective, randomized study to explore the morbidity and mortality in patients dialyzed with the Theranova HDx in comparison with online hemodiafiltration. Clinical Kidney Journal. 2023; 16(11)DOI:10.1093/ckj/sfad128. PMID:37915938. IF:3.900(Q1/2D).